Partnerships

Eli Lilly plans to acquire Adverum Biotechnologies for $3.56 per share, enhancing its portfolio in innovative genetic medicines for vision restoration.

The acquisition aims to enhance Alkermes' entry into the sleep medicine market and expanding its product portfolio.

The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.

Pharmaceutical companies enhance cancer and autoimmune disease treatments through strategic collaborations, advancing innovative therapies, and improving patient outcomes.

The biopharmaceutical sector sees major acquisitions, enhancing capabilities in RNA therapies and rare diseases, with key players like BioCryst and Bristol Myers Squibb leading the charge.

Algen Biotechnologies partners with AstraZeneca to enhance AI-driven drug discovery, targeting chronic inflammatory conditions for innovative therapeutic solutions.

Chiesi Group partners with Arbor Biotechnologies to advance gene editing therapies for rare diseases, focusing on primary hyperoxaluria type 1.

The new funding is expected to fuel clinical progress for Alchemab’s muscle atrophy candidate and expand its AI-driven pipeline targeting immune and neurological diseases.

The deal gives Avadel global rights to develop and market valiloxybate for narcolepsy and idiopathic hypersomnia, with a once-at-bedtime, sodium-free formulation designed to improve patient convenience and outcomes.

The collaboration provides BioArctic with an upfront payment of $30 million and potential milestone and royalty payments as the companies explore a novel drug candidate for severe neurological disorders.

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward regulatory approval and patient access.

The collaboration will explore RNA-based small molecule drug candidates aimed at neurological conditions where existing treatment options remain limited.

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients with relapsed or refractory follicular lymphoma.

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia and expanding its cardiometabolic portfolio.

The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio as the company advances its liver disease research and development efforts.

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from industry veterans.

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for desmoid tumors and Gomekli for symptomatic plexiform neurofibromas.

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming responsibility for global development and commercialization if it exercises its option.

During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies and precision medicine for high-burden diseases.

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 billion, in addition to single-digit royalties.

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions and alliances focused on pain, obesity, and neuroscience.

Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the option to pursue additional indications and combination therapies independently.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash consideration, including $1.2 billion upfront and up to $800 million in milestone payments.

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders.